
FOUNDERS BIOGRAPHY

TimeTeller® is a spin-off from Charité – Universitätsmedizin Berlin, one of Germany's leading university hospitals and biomedical research institutions. The company was founded in Hamburg in 2023 to translate cutting-edge research in circadian biology into practical diagnostic tools that enable personalised and time-based medicine.

TimeTeller has three co-founders: Prof. Dr. Angela Relógio, Dr. Benjamin Dose, and the Charité – Universitätsmedizin Berlin, represented by its technology transfer partner ascension GmbH.

Prof. Dr. Angela Relógio

CEO & Co-Founder

Prof. Dr. Angela Relógio is a systems biologist, entrepreneur, and internationally recognized expert in circadian biology, systems medicine, and computational modelling.

She currently serves as Professor of Systems Medicine at the Medical School Hamburg (MSH). She has led interdisciplinary research groups investigating how the body's biological clock regulates gene activity, cellular processes, and disease mechanisms.

Her research focuses particularly on understanding how circadian rhythms influence disease development and treatment responses, especially in cancer biology. While leading research groups at Charité – Universitätsmedizin Berlin and later at Medical School Hamburg, she pioneered work integrating systems biology, molecular biology, and mathematical modelling to uncover disease-driving mechanisms.

Prof. Relógio holds a joint PhD in Biomedical Sciences (Molecular and Cellular Biology) from the University of Lisbon and the European Molecular Biology Laboratory (EMBL), graduating summa cum laude. She also holds a diploma in Technological-Physics Engineering and postgraduate training in Biophysics and Biomedical Engineering from the University of Lisbon. She completed her habilitation in Molecular Biology and Bioinformatics at Charité – Universitätsmedizin Berlin in 2016.

Her scientific career includes research positions at EMBL Heidelberg and Charité, where she later became Research Group Leader for Systems Biology of Cancer and a faculty member of the Berlin School of Integrative Oncology. She has authored more than 80 scientific publications including reviews, conference and research articles, and has been invited keynote speaker at numerous national and international events.

Driven by the insight that the effectiveness and side effects of treatments can strongly depend on biological timing, Prof. Relógio translated her scientific discoveries into a diagnostic technology designed to measure an individual's internal clock. This work ultimately led to the creation of TimeTeller®, with the goal of bringing chronomedicine into clinical practice and preventive healthcare.

Through TimeTeller, she aims to bridge the gap between academic research and medical innovation, empowering patients and healthcare professionals to use circadian rhythm-based insights to improve health outcomes.

Dr. Benjamin Dose

COO & Co-Founder

Dr. Benjamin Dose is Co-Founder and Chief Operating Officer of TimeTeller®, bringing expertise in biochemistry, regulatory science, and healthcare innovation.

He joined the TimeTeller project in 2021 during its development phase and became a founding member when the company was established in 2023. His work focuses on translating scientific discoveries into scalable, regulatory-compliant and clinically implementable healthcare solutions.

Dr. Dose holds a PhD in Biochemistry and has a scientific background in molecular biology and life sciences, with research experience in several international research environments including DESY (Deutsches Elektronen-Synchrotron), the University of Cambridge, and the Leibniz Institute for Natural Product Research and Infection Biology. During his academic career he worked in multidisciplinary research teams investigating molecular mechanisms of biological processes and contributed to several peer-reviewed scientific publications.

Building on this scientific foundation, Dr. Dose developed expertise at the interface of regulation, clinical evidence generation, and healthcare market access, supporting the translation of biomedical innovations into medical technologies that can be implemented within real-world healthcare systems. His work includes regulatory strategy under EU MDR and IVDR, clinical evaluation and evidence synthesis, as well as understanding reimbursement pathways within the German statutory healthcare system (GKV).

At TimeTeller, he leads operations, regulatory strategy, and business development, ensuring that the company's circadian rhythm-based diagnostic technology can successfully move from research into clinical practice. His responsibilities include

coordinating regulatory planning, operational processes, financial and organizational structures, and strategic partnerships.

Dr. Dose is particularly interested in how scientific innovation can be translated into solutions that reach patients and contribute to more personalized approaches to prevention and treatment. Through his work at TimeTeller, he contributes to advancing chronomedicine and enabling healthcare systems to make use of circadian biology to improve patient outcomes.

Charité – Universitätsmedizin Berlin

Institutional Co-Founder

Charité – Universitätsmedizin Berlin is one of Europe's largest and most prestigious university hospitals. The institution combines cutting-edge biomedical research with patient-centred clinical care and is recognized internationally for its contributions to medical science.

As the academic environment in which the underlying research for TimeTeller was developed, Charité plays an important role as an institutional co-founder of the company. The university hospital is represented in the spin-off by ascension GmbH, its technology transfer partner supporting the commercialization of innovative medical technologies.